Home›Companies›Biotech & Pharma›Memento Medicines

Memento Medicines, Inc.

Develops antibody therapies for people with retinal diseases.

Updated Nov 10, 2026·Latest SEC filing Jun 16, 2026·Suggest an edit

About Memento Medicines

Memento Medicines is a private company based in Boston, Massachusetts, incorporated in 2025 in Delaware. It has reported $38,000,159 raised in one offering on Form D since June 2026. Its chief executive is Naveen Daryani.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 3, 2026Jun 16, 2026$38,000,159of $93.0M target7$5.4MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Memento Medicines's Form D filed Jun 16, 2026.

WB
William Bonificio
Executive officer and promoter
Also an executive officer and promoter at Lonestar Medicines and Navigator Medicines.
MK
ST
Stephen Thomas
Executive officer and promoter
Also a chief executive officer and director at Lonestar Medicines and a co-founder and CEO, sera medicine, director at Navigator Medicines.
ND
Naveen Daryani
CEO and director
Also an executive officer at Lonestar Medicines and Navigator Medicines.
VK

Sources

  1. SECMemento Medicines, Inc. filing history
  2. InvestorMemento Medicines launch announcement